Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: Prevalence of painful somatic symptoms, functioning and health status

被引:38
|
作者
Romera, Irene [1 ]
Fernandez-Perez, Sabela [1 ]
Luis Montejo, Angel [2 ]
Caballero, Fernando [3 ]
Caballero, Luis [4 ]
Angel Arbesu, Jose [5 ]
Delgado-Cohen, Helena [1 ]
Desaiah, Durisala [6 ]
Polavieja, Pepa [1 ]
Gilaberte, Inmaculada [1 ]
机构
[1] Lilly Spain, Dept Clin Res, Madrid, Spain
[2] Univ Hosp Salamanca, Sch Med, Salamanca, Spain
[3] Serv Madrileno Salad, Hlth Area 6, Primary Care Res Dept, Madrid, Spain
[4] Hosp Univ Puerta de Hierro, Madrid, Spain
[5] Ctr Salud Eria, Oviedo, Spain
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
Generalized anxiety disorder; Co-morbid major depressive disorder; Painful physical symptoms; Epidemiological study; Primary care; PHYSICAL SYMPTOMS; MENTAL-DISORDERS; COMORBIDITY; IMPAIRMENT; IMPACT; SCALE;
D O I
10.1016/j.jad.2010.05.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Painful physical symptoms (PPS) have received little attention in patients with generalized anxiety disorder (GAD). The objective of the present study was to assess the prevalence of PPS in patients with GAD vs patients with GAD and co-morbid major depressive disorder (MDD) and a control group (patients neither with GAD nor MDD). Methods: This is a cross-sectional, multi-center, epidemiological study, in primary care. Patients were screened for GAD (HADS-A), followed by a diagnosis confirmation (MINI). Patients were considered to have PPS when VAS overall pain score > 30. Functioning and health status was assessed (SDS, EUROQoL-5D). Relationships between the presence of PPS and functioning and health status was analyzed (ANCOVA models). Results were adjusted for confounding factors. Results: Of 7152 patients, 1546 (22%) screened positive for GAD, 981 (14%) had confirmed GAD diagnosis, of whom 559 (8%) had GAD with co-morbid MDD and 422 (6%) had GAD alone. Of the 5292 (74%) patients screened negative for GAD, 336 (5%) were confirmed as controls. PPS in patients with GAD were twice as prevalent as in the control group: 59.0% vs. 28.3%; p < 0.001. The presence of co-morbid MDD was associated with a significantly higher prevalence of PPS: 78.0% vs. 59.0%; p < 0.001. PPS were significantly associated with functioning and health status impairment (p < 0.001) both in GAD alone and in GAD and co-morbid MDD compared with controls. Limitations: Results do not prove causal relationships. Conclusions: Our results support the clinical relevance of PPS in patients suffering from GAD; therefore they need to be considered when evaluating the patient. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:160 / 168
页数:9
相关论文
共 50 条
  • [21] FREQUENCY OF BIPOLAR AFFECTIVE DISORDER IN PATIENTS WITH MAJOR DEPRESSIVE EPISODE WITH OR WITHOUT PSYCHIATRIC CO-MORBID DISORDERS
    Kucukalic, Abdulah
    Bravo-Mehmedbasic, Alma
    Kulenovic, Alma Dzubur
    [J]. PSYCHIATRIA DANUBINA, 2012, 24 : S321 - S325
  • [22] Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder
    Meighen, Karen G.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (01) : 121 - 127
  • [23] Phase-based psychotherapy as a treatment for dissociative identity disorder co-morbid with major depressive disorder
    Ergul, Humeyra
    Yanik, Medaim
    Uysal, Burcu
    [J]. INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2023, 58 : 1024 - 1024
  • [24] MEDICAL TREATMENT OF ALCOHOL DEPENDENCE IN PATIENTS WITH CO-MORBID ANXIETY- DEPRESSIVE DISORDER
    Pasholli, Sevime Sallahi
    Vaskova, Pavlina
    Kostadinovska, Marija
    Vasilevska-Calovska, Kristina
    [J]. PSYCHIATRIA DANUBINA, 2018, 30 : S67 - S68
  • [25] Changes in sleep outcomes with hypnotic placebo in patients with primary insomnia (PI) and insomnia co-morbid with major derpessive disorder (MDD) or generalized anxiety disorder (GAD)
    Rubens, Robert
    McCall, W. Vaughn
    Wilson, Phebe
    Schaefer, Kendyl
    Fava, Maurizio
    Pollack, Mark
    Roth, Thomas
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 85S - 85S
  • [26] Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates
    Bailey, Freddie
    Mondragon-Shem, Karina
    Haines, Lee Rafuse
    Olabi, Amina
    Alorfi, Ahmed
    Ruiz-Postigo, Jose Antonio
    Alvar, Jorge
    Hotez, Peter
    Adams, Emily R.
    Velez, Ivan D.
    Al-Salem, Waleed
    Eaton, Julian
    Acosta-Serrano, Alvaro
    Molyneux, David H.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (02):
  • [27] Initial investigation of behavioral activation therapy for co-morbid major depressive disorder and obesity
    Pagoto, Sherry
    Bodenlos, Jamie S.
    Schneider, Kristin L.
    Olendzki, Barbara
    Spates, C. Richard
    [J]. PSYCHOTHERAPY, 2008, 45 (03) : 410 - 415
  • [28] Co-Morbid Recurrent Headaches and Major Depressive Disorder: An RCT of Cognitive Behavior Therapy
    Martin, P. R.
    [J]. CEPHALALGIA, 2013, 33 (S8) : 95 - 95
  • [29] Major depressive disorder, somatic pain, and health care costs in an urban primary care practice
    Gameroff, Marc J.
    Olfson, Mark
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (08) : 1232 - 1239
  • [30] The role of leptin in indirectly mediating "somatic anxiety" symptoms in major depressive disorder
    Zhu, Yue
    Wei, Yange
    Duan, Jia
    Li, Jianing
    Zhang, Ran
    Sun, Jiaze
    Wang, Pengshuo
    Liu, Zhuang
    Lv, Jing
    Wei, Shengnan
    Jiang, Xiaowei
    Wang, Fei
    Tang, Yanqing
    [J]. FRONTIERS IN PSYCHIATRY, 2022, 13